146 related articles for article (PubMed ID: 21134504)
1. Steady-state pharmacokinetics of an extended-regimen oral contraceptive with continuous estrogen.
DiLiberti CE; O'Leary CM; Hendy CH; Waters DH; Margolis MB
Contraception; 2011 Jan; 83(1):55-61. PubMed ID: 21134504
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the pharmacokinetic profile of an ascending-dose, extended-regimen combined oral contraceptive to those of other extended regimens.
Darwish M; Bond M; Ricciotti N; Hsieh J; Fiedler-Kelly J; Grasela T
Reprod Sci; 2014 Nov; 21(11):1401-10. PubMed ID: 24647707
[TBL] [Abstract][Full Text] [Related]
3. Effect of mavoglurant (AFQ056), a selective mGluR5 antagonist, on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and levonorgestrel in healthy women.
Sivasubramanian R; Chakraborty A; Rouzade-Dominguez ML; Neelakantham S; Jakab A; Mensinga T; Legangneux E; Woessner R; Ufer M
Int J Clin Pharmacol Ther; 2015 Jul; 53(7):550-6. PubMed ID: 25943176
[TBL] [Abstract][Full Text] [Related]
4. Effect of empagliflozin on the steady-state pharmacokinetics of ethinylestradiol and levonorgestrel in healthy female volunteers.
Macha S; Mattheus M; Pinnetti S; Woerle HJ; Broedl UC
Clin Drug Investig; 2013 May; 33(5):351-7. PubMed ID: 23512637
[TBL] [Abstract][Full Text] [Related]
5. A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrel.
Endrikat J; Blode H; Gerlinger C; Rosenbaum P; Kuhnz W
Eur J Contracept Reprod Health Care; 2002 Jun; 7(2):79-90. PubMed ID: 12201326
[TBL] [Abstract][Full Text] [Related]
6. Effect of the hepatitis C virus protease inhibitor faldaprevir on the pharmacokinetics of an oral contraceptive containing ethinylestradiol and levonorgestrel in healthy female volunteers.
Sabo JP; Lang B; Elgadi M; Huang F
Antimicrob Agents Chemother; 2015 Jan; 59(1):514-9. PubMed ID: 25385099
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum.
Kuhnz W; Staks T; Jütting G
Contraception; 1994 Dec; 50(6):563-79. PubMed ID: 7705098
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of ethinylestradiol and levonorgestrel after administration of two oral contraceptive preparations.
Carol W; Klinger G; Jäger R; Kasch R; Brandstädt A
Exp Clin Endocrinol; 1992; 99(1):12-7. PubMed ID: 1628691
[TBL] [Abstract][Full Text] [Related]
9. Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on the pharmacokinetics of oral contraceptives, warfarin, and digoxin in healthy participants.
Devineni D; Manitpisitkul P; Vaccaro N; Bernard A; Skee D; Mamidi RN; Tian H; Weiner S; Stieltjes H; Sha S; Rothenberg P
Int J Clin Pharmacol Ther; 2015 Jan; 53(1):41-53. PubMed ID: 25345427
[TBL] [Abstract][Full Text] [Related]
10. Atogepant Has No Clinically Relevant Effects on the Pharmacokinetics of an Ethinyl Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female Participants.
Ankrom W; Xu J; Vallee MH; Dockendorf MF; Armas D; Boinpally R; Min KC
J Clin Pharmacol; 2020 Sep; 60(9):1157-1165. PubMed ID: 32297990
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics of fingolimod (FTY720) and a combined oral contraceptive coadministered in healthy women: drug-drug interaction study results.
David OJ; Ocwieja M; Meiser K; Emotte C; Jakab A; Wemer J; den Daas I; Schmouder R
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):540-4. PubMed ID: 22735460
[TBL] [Abstract][Full Text] [Related]
12. Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial.
Edelman AB; Cherala G; Munar MY; McInnis M; Stanczyk FZ; Jensen JT
Contraception; 2014 Nov; 90(5):550-6. PubMed ID: 25070547
[TBL] [Abstract][Full Text] [Related]
13. Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women.
Griffith SG; Dai Y
Clin Ther; 2004 Dec; 26(12):2056-65. PubMed ID: 15823769
[TBL] [Abstract][Full Text] [Related]
14. Continuous, daily levonorgestrel/ethinyl estradiol vs. 21-day, cyclic levonorgestrel/ethinyl estradiol: efficacy, safety and bleeding in a randomized, open-label trial.
Teichmann A; Apter D; Emerich J; Greven K; Klasa-Mazurkiewicz D; Melis GB; Spaczynski M; Grubb GS; Constantine GD; Spielmann D
Contraception; 2009 Dec; 80(6):504-11. PubMed ID: 19913143
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic and pharmacokinetic evaluation of coadministration of lacosamide and an oral contraceptive (levonorgestrel plus ethinylestradiol) in healthy female volunteers.
Cawello W; Rosenkranz B; Schmid B; Wierich W
Epilepsia; 2013 Mar; 54(3):530-6. PubMed ID: 23360419
[TBL] [Abstract][Full Text] [Related]
16. Treatment with liraglutide--a once-daily GLP-1 analog--does not reduce the bioavailability of ethinyl estradiol/levonorgestrel taken as an oral combination contraceptive drug.
Jacobsen LV; Vouis J; Hindsberger C; Zdravkovic M
J Clin Pharmacol; 2011 Dec; 51(12):1696-703. PubMed ID: 21228406
[TBL] [Abstract][Full Text] [Related]
17. BMI, pharmacokinetics, and OCP failure.
Cherala G; Edelman A
Contraception; 2010 Dec; 82(6):582; author reply 581-2. PubMed ID: 21074028
[No Abstract] [Full Text] [Related]
18. No clinically relevant drug-drug interactions when dalcetrapib is co-administered with a monophasic oral contraceptive (Microgynon® 30).
Young A; Anzures-Cabrera J; Derks M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):248-56. PubMed ID: 22456295
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and adhesion of the Agile transdermal contraceptive patch (AG200-15) during daily exposure to external conditions of heat, humidity and exercise.
Archer DF; Stanczyk FZ; Rubin A; Foegh M
Contraception; 2013 Feb; 87(2):212-9. PubMed ID: 23158806
[TBL] [Abstract][Full Text] [Related]
20. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial.
Archer DF; Stanczyk FZ; Rubin A; Foegh M
Contraception; 2012 Jun; 85(6):595-601. PubMed ID: 22133660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
